Herbert Struemper

934 total citations
35 papers, 469 citations indexed

About

Herbert Struemper is a scholar working on Radiology, Nuclear Medicine and Imaging, Immunology and Rheumatology. According to data from OpenAlex, Herbert Struemper has authored 35 papers receiving a total of 469 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Radiology, Nuclear Medicine and Imaging, 14 papers in Immunology and 12 papers in Rheumatology. Recurrent topics in Herbert Struemper's work include Monoclonal and Polyclonal Antibodies Research (17 papers), Systemic Lupus Erythematosus Research (11 papers) and Multiple Myeloma Research and Treatments (8 papers). Herbert Struemper is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (17 papers), Systemic Lupus Erythematosus Research (11 papers) and Multiple Myeloma Research and Treatments (8 papers). Herbert Struemper collaborates with scholars based in United States, United Kingdom and Netherlands. Herbert Struemper's co-authors include David A. Roth, Cecil Chen, Wendy Cai, David Gordon, Roxanne C. Jewell, Chetan Rathi, Geraldine Ferron‐Brady, Andrea van Elsas, Saroja Ramanujan and Nadine A. Defranoux and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Herbert Struemper

34 papers receiving 447 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Herbert Struemper United States	14	233	167	137	127	113	35	469
Vincent Chow United States	15	354 1.5×	126 0.8×	124 0.9×	219 1.7×	100 0.9×	44	639
Liviawati Sutjandra United States	7	64 0.3×	88 0.5×	24 0.2×	172 1.4×	102 0.9×	9	330
Melissa Cheu United States	7	185 0.8×	133 0.8×	28 0.2×	47 0.4×	177 1.6×	14	530
Anson K. Abraham United States	12	110 0.5×	103 0.6×	14 0.1×	138 1.1×	152 1.3×	17	353
Birge Berns United Kingdom	6	285 1.2×	45 0.3×	21 0.2×	308 2.4×	132 1.2×	12	525
Florence Hourcade‐Potelleret Switzerland	16	74 0.3×	140 0.8×	51 0.4×	195 1.5×	130 1.2×	27	567
Julie A. Di Paolo United States	9	168 0.7×	55 0.3×	148 1.1×	134 1.1×	100 0.9×	17	521
Paul M. Diderichsen United States	10	45 0.2×	24 0.1×	57 0.4×	119 0.9×	101 0.9×	38	341
Jason B. Litten United States	9	130 0.6×	29 0.2×	19 0.1×	132 1.0×	202 1.8×	21	537

Countries citing papers authored by Herbert Struemper

Since Specialization

Citations

This map shows the geographic impact of Herbert Struemper's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Herbert Struemper with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Herbert Struemper more than expected).

Fields of papers citing papers by Herbert Struemper

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Herbert Struemper. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Herbert Struemper. The network helps show where Herbert Struemper may publish in the future.

Co-authorship network of co-authors of Herbert Struemper

This figure shows the co-authorship network connecting the top 25 collaborators of Herbert Struemper. A scholar is included among the top collaborators of Herbert Struemper based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Herbert Struemper. Herbert Struemper is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Goulooze, Sebastiaan C., Morris Muliaditan, Alejandro Mantero, et al.. (2025). Tutorial on Conditional Simulations With a Tumor Size‐Overall Survival Model to Support Oncology Drug Development. CPT Pharmacometrics & Systems Pharmacology. 14(4). 640–650. 1 indexed citations

Struemper, Herbert, Chetan Rathi, Morris Muliaditan, et al.. (2025). Development of a Joint Tumor Size–Overall Survival Modeling and Simulation Framework Supporting Oncology Development Decision‐Making. CPT Pharmacometrics & Systems Pharmacology. 14(6). 1006–1017. 1 indexed citations

Polireddy, Kishore, Xialin Chen, Adekemi Taylor, et al.. (2025). Population Pharmacokinetics for Belantamab Mafodotin Monotherapy and Combination Therapies in Patients with Relapsed/Refractory Multiple Myeloma. Clinical Pharmacokinetics. 64(6). 925–942. 2 indexed citations

Samant, Tanay S., Herbert Struemper, Morris Muliaditan, et al.. (2024). P4.11E.28 Pharmacological Comparison of Dostarlimab and Pembrolizumab in Metastatic Non-Small Cell Lung Cancer in PERLA. Journal of Thoracic Oncology. 19(10). S407–S408.

Rathi, Chetan, et al.. (2023). Longitudinal efficacy and safety modeling and simulation framework to aid dose selection of belantamab mafodotin for patients with multiple myeloma. CPT Pharmacometrics & Systems Pharmacology. 12(10). 1411–1424. 8 indexed citations

Ferron‐Brady, Geraldine, Chetan Rathi, Herbert Struemper, et al.. (2021). Exposure–Response Analyses for Therapeutic Dose Selection of Belantamab Mafodotin in Patients With Relapsed/Refractory Multiple Myeloma. Clinical Pharmacology & Therapeutics. 110(5). 1282–1292. 15 indexed citations

Hug, Bruce A., et al.. (2020). Safety, Pharmacokinetics, and Pharmacodynamics of the TLR4 Agonist GSK1795091 in Healthy Individuals: Results from a Randomized, Double-blind, Placebo-controlled, Ascending Dose Study. Clinical Therapeutics. 42(8). 1519–1534.e33. 17 indexed citations

Ji, Beulah, et al.. (2020). Pharmacokinetics of Belimumab in Children With Systemic Lupus Erythematosus. Clinical Pharmacology in Drug Development. 10(6). 622–633. 13 indexed citations

Struemper, Herbert, et al.. (2017). Population Pharmacokinetic and Pharmacodynamic Analysis of Belimumab Administered Subcutaneously in Healthy Volunteers and Patients with Systemic Lupus Erythematosus. Clinical Pharmacokinetics. 57(6). 717–728. 22 indexed citations

10.

Bonate, Peter L., Malidi Ahamadi, Nageshwar Budha, et al.. (2016). Methods and strategies for assessing uncontrolled drug–drug interactions in population pharmacokinetic analyses: results from the International Society of Pharmacometrics (ISOP) Working Group. Journal of Pharmacokinetics and Pharmacodynamics. 43(2). 123–135. 21 indexed citations

11.

Sheikh, Saira Z., N. L. Fox, Anne E. Hammer, et al.. (2016). AB0416 Reliability and Safety of A Novel Autoinjector for Self-Administration of Subcutaneous Belimumab in Patients with Systemic Lupus Erythematosus (SLE). Annals of the Rheumatic Diseases. 75. 1048–1049. 1 indexed citations

12.

Infante, Jeffrey R., Christoph M. Ahlers, F. Stephen Hodi, et al.. (2016). ENGAGE-1: A first in human study of the OX40 agonist GSK3174998 alone and in combination with pembrolizumab in patients with advanced solid tumors.. Journal of Clinical Oncology. 34(15_suppl). TPS3107–TPS3107. 13 indexed citations

13.

Struemper, Herbert, Jane Gilbert, Matthew E. Barton, et al.. (2015). Relative Bioavailability of a Single Dose of Belimumab Administered Subcutaneously by Prefilled Syringe or Autoinjector in Healthy Subjects. Clinical Pharmacology in Drug Development. 5(3). 208–215. 26 indexed citations

14.

Struemper, Herbert, Jane Gilbert, James Groark, et al.. (2015). THU0403 A Randomised, Open-Label Study to Evaluate the Relative Bioavailability of a Single Dose of Belimumab Administered Subcutaneously by Prefilled Syringe or Autoinjector. Annals of the Rheumatic Diseases. 74. 342–343. 1 indexed citations

15.

Struemper, Herbert, Mark Sale, Bela Patel, et al.. (2014). Population pharmacokinetics of ofatumumab in patients with chronic lymphocytic leukemia, follicular lymphoma, and rheumatoid arthritis. The Journal of Clinical Pharmacology. 54(7). 818–827. 22 indexed citations

16.

Simpkins, Fiona, Aurea E. Flores, Christina Chu, et al.. (2013). Chemoimmunotherapy Using Pegylated Liposomal Doxorubicin and Interleukin-18 in Recurrent Ovarian Cancer: A Phase I Dose-Escalation Study. Cancer Immunology Research. 1(3). 168–178. 41 indexed citations

17.

Struemper, Herbert, Cecil Chen, & Wendy Cai. (2013). Population Pharmacokinetics of Belimumab Following Intravenous Administration in Patients With Systemic Lupus Erythematosus. The Journal of Clinical Pharmacology. 53(7). 711–720. 44 indexed citations

18.

Robertson, Michael J., Justin Kline, Herbert Struemper, et al.. (2013). A Dose-Escalation Study of Recombinant Human Interleukin-18 in Combination With Rituximab in Patients With Non-Hodgkin Lymphoma. Journal of Immunotherapy. 36(6). 331–341. 29 indexed citations

19.

Robertson, Michael J., John W. Bauman, Olivia Gardner, et al.. (2011). Phase I Trial Evaluating the Safety and Biological Activity of Iboctadekin (rhIL-18) in Combination with Rituximab in Patients with CD20+ B Cell Non-Hodgkin's Lymphoma,. Blood. 118(21). 3697–3697. 1 indexed citations

20.

Rullmann, J.A.C., et al.. (2005). Systems biology for battling rheumatoid arthritis: Application of the Entelos PhysioLab platform. PubMed. 152(4). 256–256. 41 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact